Auto Owners Insurance Co Purchases 69,108,368 Shares of Johnson & Johnson $JNJ

Key Points

• Auto Owners Insurance Co dramatically increased its Johnson & Johnson stake in the fourth quarter, buying over 69 million additional shares and ending with about 2.88% of the company worth roughly $1.44 billion.
• Johnson & Johnson recently beat quarterly earnings and revenue estimates, reporting EPS of $2.70 on revenue of $24.06 billion, while also issuing FY 2026 EPS guidance of 11.45 to 11.65.
• The company raised its quarterly dividend to $1.34 per share from $1.30, and recent updates also point to positive pipeline news for Erleada and a planned more than $1 billion manufacturing investment in Florida.

Auto Owners Insurance Co boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 22,225.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,419,308 shares of the company's stock after buying an additional 69,108,368 shares during the period. Johnson & Johnson makes up 0.3% of Auto Owners Insurance Co's holdings, making the stock its 28th biggest holding. Auto Owners Insurance Co owned about 2.88% of Johnson & Johnson worth $1,436,633,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of JNJ. Blueline Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $25,000. Cresta Advisors Ltd. acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $26,000. DecisionPoint Financial LLC increased its holdings in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after purchasing an additional 75 shares in the last quarter. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after buying an additional 49 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ opened at $228.37 on Friday. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The company has a market cap of $549.73 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 2.24 and a beta of 0.26. The company's fifty day moving average price is $230.61 and its two-hundred day moving average price is $228.09. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. During the same period last year, the company earned $2.77 earnings per share. The business's revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is presently 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company's stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Citigroup raised their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. Morgan Stanley set a $283.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $265.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Finally, The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.